Background: Our single-institution series, now including 53 metastatic MLS patients (pts) treated with trabectedin (T), was reviewed focusing on the use of surgery of residual disease. Methods: Since ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback